06628.HK
Transcenta Holding Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.74
+9.70%Oct 28, 2026, 09:53 UTC
Touyun Biotech Group Ltd.’s non-wholly owned subsidiary Transcenta Holding Ltd. and Touyun Biotech Group Ltd. jointly established a research and development center under a cooperation agreement.
Source:Oct 28, 2026, 09:46 UTC
Touyun Biotech Group Ltd.’s non-wholly owned subsidiary Transcenta Holding Ltd. and Tianfu Yongxing Laboratory established the Advanced Thermal Control Materials and Equipment Joint Transformation Center under a cooperation agreement.
Source:Oct 22, 2026, 04:09 UTC
Transcenta Holding Ltd. said its drug Jentai (tinengotinib) entered commercial sales after its first batch was produced and shipped and the first prescription was issued at Peking University Cancer Hospital.
Source:Oct 20, 2026, 04:39 UTC
Transcenta Holding Ltd. said the transfer of its CDMO assets is underway and that it expects to receive additional proceeds by the end of 2026.
Source:Oct 20, 2026, 04:34 UTC
Transcenta Holding Ltd. received the first net-of-tax installment of RMB 95 million from WuXi Biologics (Cayman), Inc. for the sale of its CDMO assets.
Source:Oct 12, 2026, 00:23 UTC
China’s National Intellectual Property Administration granted an invention patent to Suzhou Transcenta Therapeutics for an anti-CLDN18.2 antibody and its diagnostic uses, covering an antibody developed for osemitamab companion diagnostics.
Source:Oct 7, 2026, 01:37 UTC
Huajian Medical said proposed tokenization of Transcenta's innovative drug development pipeline has been temporarily suspended after reassessing regulatory and implementation requirements.
Source:Sep 21, 2026, 02:24 UTC
TransThera Sciences' self-developed multi-target small molecule kinase inhibitor tinengotinib (Jie'antai) was included in the Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of biliary tract malignancies as a Class II recommendation, Category 2A, for advanced biliary tract cancer.
Source:Aug 26, 2026, 10:27 UTC
Pharmaceutical company Yaojie Ankang (02617.HK) reported interim results for the six months ended June 2026, with revenue of RMB 35.46 million and a narrowed net loss of RMB 95.47 million, compared with a loss of RMB 123 million in the same period last year.
Source:Aug 6, 2026, 23:32 UTC
Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.
Source:Jul 28, 2026, 00:08 UTC
CStone Pharmaceuticals successfully completed the renewal and extension of approximately RMB 85 million in bank loans.
Source: